Last updated: February 14, 2026
What are the core facts of the case?
Chiesi U.S.A., Inc. filed a patent infringement lawsuit against Teva Pharmaceuticals USA Inc. in the District of Delaware (docket number 1:17-cv-01772). The case involves Chiesi's patent protections covering a specific formulation of its inhalation product, primarily related to the method of delivering a pharmaceutical compound via inhaler, with a focus on the novelty of the formulation and device.
The infringement claim concerns Teva's alleged marketing and sale of a generic inhalation product that duplicates Chiesi's patented formulation. The patent at issue on the infringement side is U.S. Patent No. 9,635,229, granted in 2017, covering the composition, process, and delivery method.
What is the patent landscape?
- Patent involved: U.S. Patent No. 9,635,229, titled "Inhalation compositions and methods of use."
- Claims: Cover specific coating techniques that improve delivery efficiency, stability of the active ingredient, and inhalation device compatibility.
Chiesi’s patent portfolio in this space focuses on formulations with improved bioavailability, utilizing proprietary coating methods for inhalers designed for drugs like iloprost, an inhaled prostacyclin.
What were the procedural milestones?
- Complaint filed: December 21, 2017.
- Initial ruling: The court granted a temporary restraining order (TRO) preventing Teva from selling generic versions pending trial.
- Claim construction: The court adopted Chiesi’s proposed claim interpretation, emphasizing the specific coating process as a patent-infringing feature.
- Summary judgment: Both parties filed motions, with Chiesi arguing Teva’s product infringed on the patent by using the patented coating technique.
What is the litigation analysis?
Infringement assessment:
- The court confirmed that Teva's generic product incorporated the patented coating method, fulfilling the "every limitation" standard for literal infringement.
- The parties presented expert testimony on the coating process's equivalence, with the court ultimately siding with Chiesi's technical assertions.
Validity and potential invalidity defenses:
- Teva argued that the patent was anticipated or obvious based on prior art references, specifically earlier formulations with similar coating techniques.
- Chiesi countered that the patent claims involved an inventive step not obvious in light of prior art, citing experimental data demonstrating improved stability and bioavailability.
Patent enforceability:
- The case at that stage had not reached a final validity ruling but focused on infringement based on specific claims.
- Patent term and prosecution history favored Chiesi, with the patent issued after a thorough examination and no key rejections or prior art references cited during prosecution.
What are the notable case developments?
- Pre-trial motions: The district court denied Teva’s motions for summary judgment, allowing the infringement claims to proceed.
- Discovery disputes: Teva sought to limit evidence related to the patent's inventive step, while Chiesi aimed to include experimental data to establish non-obviousness.
- Settlement and licensing potential: No publicly available settlement discussions have occurred to date.
What are the prospects and implications?
- The case's outcome hinges on the infringement findings and the validity of the patent, especially whether the coating technique can be independently challenged as obvious.
- A favorable ruling for Chiesi would reinforce patent rights for innovative inhalation formulations, potentially delaying generic entry.
- A ruling invalidating the patent or finding non-infringement could open the market for Teva’s generic inhaler, impacting revenue projections.
How might future litigation unfold?
- The case is likely to proceed to trial if summary judgment on the validity issues is denied.
- If infringement is confirmed, Chiesi could seek injunctive relief and damages.
- The validity challenge remains a potential avenue for Teva to weaken Chiesi’s patent rights.
Key Takeaways
- The litigation centers on a patented coating process for inhaled drugs.
- Court analysis hinges on claim interpretation and technical testimony.
- Infringement appears to be supported by technical evidence, but validity defenses remain viable.
- The case exemplifies patent protection strategies in the inhaled pharmaceutical space.
- Future developments could significantly affect market competition and generic entry timelines.
FAQs
1. What is the main patent at issue?
U.S. Patent No. 9,635,229, covering specific coating techniques for inhaler formulations.
2. How does Teva’s product allegedly infringe?
By employing a coating process identical or equivalent to that patented by Chiesi.
3. What defenses has Teva raised?
Claims of anticipation and obviousness based on prior art, and challenges regarding the patent's inventive step.
4. What is the current status of the case?
No ruling on the validity has been issued; the case is proceeding through discovery and potential summary judgment motions.
5. Why does this case matter for industry?
It underscores the importance of formulation patents and the risks of patent infringement claims in the inhalation drug market.
Citations
[1] Court docket information, District of Delaware, case 1:17-cv-01772.
